AbCellera Biologics (ABCL) Nyanmɛn Kpɛn
Nɛnɛn kpanlan$12.72Kpɛn 25 Sep 2026 19:59 UTC
Chɛ̀ndʒ+0.47%
AI bɛ́nɛ́nɛ́: ABCL
AI bɛ sɔhɛn sɛn na ɛbɛ yɛ a ɛwɔ nna a ɛdi akyi, nnwɔtwe no awieeɛ ne bosome no awieeɛ. Nsakraeɛ no yɛ nea wɔhwɛ firi sika a ɛwɔ hɔ seesei. Eyinom yɛ nkyɛmu nhyehyɛeɛ, ɛnyɛ nkyɛmu a wɔde bɛyɛ adwuma.
Prix su les 6 mois derniers
Premium ɛn nyɛ AI sika tɔnɔw 1 da, 1 kɛsɛli kɛn 1 bɛn fɔlɔ ni sika tɔnɔw a ni ahunye bɛɛ.
Yɛ́lɛ́ Premium🔒 Nzɛnkan nyinmɛn
Kpɛnɛn nyanmiɛn su lɛlɛ su — kpɛnɛn nyanmiɛn su lɛlɛ kun'n su, su'n su kpɛnɛn su lɛlɛ kun'n su — yɛ Premium su.
Yɛ́lɛ́ PremiumNyanmiɛn nɛnɛn
AbCellera Biologics Inc. operates as a pharmaceutical company. The company researches and develops next-generation therapeutic antibodies using a combination of technologies, including patented immunizations, microfluidics, high-throughput imaging, genomics, computing, and laboratory automation. AbCellera Biologics serves customers in Canada.
